- Click on the slides below for a comparison of both guidelines’ treatment algorithms
- Seferović PM, Vardas P, Jankowska EA, et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. Eur J Heart Fail 2021;23:906-914.
The majority of heart failure (HF) patients are not prescribed the correct medication/medication combinations due to the current ‘one size fits all’ approach to treatment. HF is a heterogeneous condition, with no single biomarker to characterise its phenotype, presenting itself differently in individuals in regards to congestion, haemodynamic status, blood pressure and kidney function. Generally, drugs presented to HF patients to improve prognosis impact their blood pressure, heart rate, renal function and potassium levels, but due to the heterogeneity of the HF phenotypes, a personalised approach to treatment is necessary. Side effects and comorbidities (both cardiovascular, such as hypertension, and non-cardiovascular, such as obesity) are necessary to consider in this approach.
Table 1 & 2: Rosano et al (2021)
- Seferović P, Vardas P, Jankowska E et al (2019). The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics, Eur J Heart Fail 23:906-914
- Rosano et al (2021). Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail 23:872–881
- McDonagh T, Metra M, Adamo M et al (2021). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal 42:3599-3726